frontline alk, egfr inhibition in non-small cell lung cancer
Published 9 years ago • 755 plays • Length 5:54Download video MP4
Download video MP3
Similar videos
-
4:37
development of alk inhibitors in advanced non-small cell lung cancer
-
7:11
second-generation alk inhibitors in non-small cell lung cancer
-
3:52
egfr non–small cell lung cancer: frontline options
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
5:53
next-generation alk inhibitors in non-small cell lung cancer
-
6:51
progression in alk nsclc after frontline therapy
-
1:01
targeting alk rearrangements in non-small cell lung cancer
-
6:46
selecting a first-line egfr inhibitor in nsclc
-
4:09
frontline afatinib in egfr-mutant nsclc
-
9:31
frontline treatment for egfr nsclc
-
7:44
next-generation targeted therapies in non-small cell lung cancer
-
8:37
alk inhibition in nsclc
-
6:04
case study: progression on alk inhibitors in nsclc
-
5:55
a case of egfr-mutant non–small cell lung cancer
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
8:44
adjuvant egfr inhibition in patients with nsclc
-
4:23
efficacy of next-generation alk inhibitors in nsclc
-
4:28
overcoming resistance to egfr inhibitors in nsclc
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc